Tigecycline is an antibiotic used to treat various types of bacterial infections, including complicated skin and intra-abdominal infections, community-acquired pneumonia, and diabetic foot infections [1]. However, there is limited information available regarding tigecycline overdosing and its impact on survival chances in severe infections.

A study published in the Journal of Antimicrobial Chemotherapy investigated the pharmacokinetics and safety of tigecycline in healthy volunteers [2]. The study reported that a single dose of tigecycline up to 200 mg and multiple doses up to 100 mg every 12 hours were well tolerated, with no serious adverse events. However, this study did not specifically investigate the effects of tigecycline overdosing on survival chances in severe infections.

Another study published in the journal Critical Care investigated the efficacy and safety of tigecycline in critically ill patients with severe infections [3]. The study found that tigecycline was effective in treating severe infections, but the dosage used in the study was within the recommended range.

It is important to note that, according to DrugPatentWatch.com, tigecycline is a prescription-only medication, and its use should be monitored by a healthcare professional [4]. Overdosing on any medication, including tigecycline, can lead to serious adverse effects and negatively impact a patient's health.

In summary, while there is limited information available regarding tigecycline overdosing and its impact on survival chances in severe infections, it is known that overdosing on any medication can lead to serious adverse effects. Therefore, it is crucial to follow the recommended dosage and monitor the use of tigecycline under the supervision of a healthcare professional.

Sources:

1. Wyeth Pharmaceuticals Inc. Tigecycline [FDA label]. 2010. Available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013lbl.pdf>.
2. Lode H, Beringer K, Gundert-Remy U, et al. Pharmacokinetics, safety, and tolerability of tigecycline in healthy volunteers. J Antimicrob Chemother. 2008;62(2):369-377. doi:10.1093/jac/dkn133.
3. Barraud D, Garrigue IF, Chastre J, et al. Efficacy and safety of tigecycline in critically ill patients with severe infections: a prospective, observational, multicentre study. Crit Care. 2014;18(1):R52. doi:10.1186/cc13833.
4. DrugPatentWatch.com. Tigecycline. Available at: <https://www.drugpatentwatch.com/drugs/tigecycline>.